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Introduction: Tau pathology is associated with a number of age-related neurodegenerative disorders. Few treatments
have been demonstrated to diminish the impact of tau pathology in mouse models and none are yet effective in
humans. Histone deacetylase 6 (HDAC6) is an enzyme that removes acetyl groups from cytoplasmic proteins, rather
than nuclear histones. Its substrates include tubulin, heat shock protein 90 and cortactin. Tubastatin A is a selective
inhibitor of HDAC6. Modification of tau pathology by specific inhibition of HDAC6 presents a potential therapeutic
approach in tauopathy.
Methods: We treated rTg4510 mouse models of tau deposition and non-transgenic mice with tubastatin
(25 mg/kg) or saline (0.9%) from 5 to 7 months of age. Cognitive behavior analysis, histology and biochemical
analysis were applied to access the effect of tubastatin on memory, tau pathology and neurodegeneration
(hippocampal volume).
Results: We present data showing that tubastatin restored memory function in rTg4510 mice and reversed
a hyperactivity phenotype. We further found that tubastatin reduced the levels of total tau, both
histologically and by western analysis. Reduction in total tau levels was positively correlated with memory
improvement in these mice. However, there was no impact on phosphorylated forms of tau, either by
histology or western analysis, nor was there an impact on silver positive inclusions histologically.
Conclusion: Potential mechanisms by which HDAC6 inhibitors might benefit the rTg4510 mouse include
stabilization of microtubules secondary to increased tubulin acetylation, increased degradation of tau
secondary to increased acetylation of HSP90 or both. These data support the use of HDAC6 inhibitors as
potential therapeutic agents against tau pathology.Introduction
Tauopathies are neurodegenerative disorders for which
there are no effective treatments. Some disorders are
caused by mutations in tau that increase the probability of
tau aggregate formation, leading to intracellular neuro-
fibrillary tangles [1]. These disorders are typically referred
to as fronto-temporal dementias. Other tauopathies occur
in different brain regions (corticobasal syndrome, progres-
sive supranuclear palsy, and so forth) [2]. The most* Correspondence: scientist.dave@gmail.com
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reproduction in any medium, provided the orcommon disorder demonstrating tau inclusions is Alzhei-
mer’s disease, where the tau pathology correlates better
than amyloid pathology with cognitive impairment [3].
Histone deacetylases (HDACs) are a family of proteins
that remove acetyl moieties attached covalently to lysine
residues in proteins. In the cell nucleus, HDACs catalyze
the deacetylation of histones and, in general, promote
chromatin condensation and repression of gene expres-
sion. In transformed cells, these enzymes are thought to
suppress proapoptotic programs, leading to unregulated
proliferation. As such, HDAC inhibitors are widely explored
as treatments for cancer [4]. There are at least 18 iso-
enzymes in the HDAC family, divided into four homology
classes. Classes I, II and IV are zinc dependent, while classl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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their enzyme activity. Class I HDACs (HDAC1, HDAC2,
HDAC3 and HDAC8) are nuclear enzymes and are the
major focus of research for anti-tumor agents. Class II
enzymes are often tissue specific, divided into class IIa
enzymes (HDAC4, HDAC5, HDAC7, HDAC9) that shuttle
between cytoplasmic and nuclear compartments and class
IIb enzymes (HDAC6 and HDAC10) that are primarily
cytoplasmic and deacetylate nonhistone proteins. HDAC6
has been shown to act upon tubulin, cortactin and HSP90.
Tubulin acetylation is associated with increased micro-
tubule stabilization [5].
The Kozikowski laboratory has synthesized a number
of compounds focusing on HDAC6. One such agent is
tubastatin A (tubastatin). This molecule was found to have
nanomolar potency in inhibiting HDAC6, but requires
micromolar or greater concentrations to inhibit most
other HDACs (>1,000× selectivity for all but HDAC8, at
50-fold selectivity). This agent was found to increase the
acetylation of tubulin in cells, but not histone H4 proteins.
Moreover, tubastatin treatment was found to be protective
against homocysteic acid-induced oxidative stress [6]. This
agent reduced the phenotype in a model of Charcot-Marie-
Tooth disease [7]. This disorder is caused by mutations
in the 27 kDa small heat shock protein HSBP1, leading
to decreased tubulin acetylation and axonal atrophy.
Tubastatin treatment prevented both the loss of acety-
lated tubulin and axonopathy. Recent observations also
demonstrate that decreases in HDAC6 activity or expres-
sion promote tau clearance [8], while HDAC6 mutations
rescued tau-induced microtubule defects in a Drosophila
model of tau pathology [9]. Given the observation that
phosphorylation of tau results in dissociation from tubulin
and decreased stabilization of microtubules [10], we hy-
pothesized that stabilizing microtubules by acetylation
might counteract the phenotype found in the rTg4510
mouse model of tauopathy. Moreover, we chose to start
injecting mice at an age when there was already memory
loss and considerable tau pathology because, even at the
earliest stages, Alzheimer patients have substantial existing
tau deposition [11]. We have thus treated 5-month-old
rTg4510 mice with the HDAC6 selective drug tubastatin
for 2 months, and monitored its effect on the behavioral
and pathological phenotype of this mouse.
Materials and methods
Drug preparation
Tubastatin was synthesized and provided by Dr A
Kozikowski [6] (University of Illinois at Chicago, Chicago,
IL, USA). The compound was dissolved in 0.9% saline to
reach a dose of 25 mg/kg body weight per animal. This
dose has been shown to efficiently inhibit HDAC6 in vivo
[7]. The solution was sonicated in the water bath for
5 minutes at room temperature until is fully solubilized.Animals and injection procedure
The production of rTg4510 mice, bred from parental
P301L tau and tTA lines, was maintained as originally
described by Santacruz and colleagues [12]. We admin-
istered experimental agents using daily intraperitoneal
injections into rTg4510 mice and nontransgenic littermates
from 5 to 7 months of age. Each group consisted of six
animals per genotype. Mice were weighed, and injected
with tubastatin (25 mg/kg) or 0.9% normal saline solution
(vehicle). Animal procedures were consistent with the rec-
ommendations of the National Research Council’s Guide
for the Care and Use of Laboratory Animals and were ap-
proved by the University of South Florida Animal Care
and Use Committee (IACUC).
Behavior methods
Behavioral analysis was carried out as described previously
[13-17]. For 3 days before testing, mice were weighed and
handled in order to habituate the mice to contact with the
experimenter. The sequence of tests over a 2-week period
were Y-maze, open field, rotarod, radial arm water maze,
water maze reversal, open pool, and fear conditioning.
Y-maze
Each animal was placed in a Y-maze for a single 5-minute
trial, during which the sequence and total number of arm
choices were recorded. Spontaneous alternation, expressed
as a percentage of total alternations, was calculated as
described [18]. If an animal made the following sequence of
arm selections (1,2,3,2,1,3,1,2), the total alternation oppor-
tunities will be six (total entries minus two) and the per-
centage alternation would be 67% (four out of six). Chance
performance is 50%
Open field
The open field is used as a standard test of general activity.
Animals were monitored for 15 minutes in a 40 cm square
open field with video tracking software, under moderate
lighting. General activity levels were evaluated by mea-
surements of horizontal activity and vertical activity. The
open field test can also be used to measure anxiety levels,
as assessed by the ratio of center distance traveled to total
distance traveled. As the natural tendency of the animal is
to avoid open areas, animals that show greater tendency
to explore in the center of the field show a lower tendency
for anxiety, or the reverse situation can indicate a higher
anxiety level.
Rotarod
Motor performance was assessed by placing the mice
onto the round portion of a circular rod that was then
accelerated slowly. Mice need to walk at the speed of
rod rotation to keep from falling. The time until falling
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each day for 2 consecutive days.
Two-day radial arm water maze
The 2-day radial arm water maze has been previously de-
scribed in detail [19]. Briefly, the radial arm water maze
consists of a 1 m pool with six swim paths (arms) radiating
out of an open central area, with a hidden escape platform
located at the end of one of the arms. On each trial, the
mouse was allowed to swim in the pool for up to 60 seconds
to find the escape platform. Incorrect arm entries or failure
to select an arm for 15 seconds were counted as errors. For
a given mouse, the platform was located in the same arm
on each trial, but the start arms were varied for each trial
so that mice rely upon spatial cues to solve the task instead
of learning motor rules (that is, second arm on the right).
On day 1, mice were given 15 trials where each block con-
sist of three trials (five blocks in total) alternating between a
visible platform (above the water) and a hidden platform
(below the water). The following day, mice were given 15
additional trials (five blocks), all using a hidden platform.
The goal arm location for sequential mice was different to
avoid odor cues from revealing the goal arm.
Radial arm water maze reversal
This test was completed on the day after the 2-day radial
arm water maze and was performed under the same
conditions. The only difference was that the goal arm
was located 180º from the original location. This reversal
task tests the ability of the mice to extinguish a learned
memory to create a novel one. Fifteen trials were given in
a single day, all with a hidden platform.
Visible platform
This was conducted in an open pool (no swim arms) to en-
sure mice can see and perform a platform task [20]. The vi-
sible platform was placed 0.8 cm above the water surface
and had an attached 10 cm× 40 cm ensign. For the test day,
the animal was placed into the pool facing the wall in each
of the four quadrants of the pool. Latency to find and ascend
the visible platform was recorded (maximum 60 seconds).
Associative fear conditioning
Fear conditioning was used to access both contextual
and cued memory formation. For these experiments, an
aversive stimulus (in this case, a mild foot shock, 0.5 mA)
was paired with an auditory conditioned stimulus (white
noise) within a novel environment. These tests were given
as follows: animals were placed in the fear conditioning
apparatus for 2.5 minutes, then a 30-second acoustic con-
ditioned stimulus (white noise, 70 dB) was coupled with a
0.5 mA shock (unconditioned stimulus) applied to the
floor grid during the last 2 seconds of the conditioned
stimulus. Two minutes later the conditioned stimulus andunconditioned stimulus were again administered, and
the mice remained in the conditioning chamber for an
additional 2 minutes. The mice were placed in the same
chamber and monitored for freezing to the context 24 hours
later (no shocks or auditory cue given). Immediately after
the contextual test, mice were placed into a novel context
and exposed to the conditioned stimulus for 3 minutes
(cued fear conditioning). Both the contextual and the cued
recall tests were performed the next day ~24 hours follow-
ing training. Learning was assessed by measuring freezing
behavior (that is, motionless position).
Tissue collection
Two months post intraperitoneal injections, mice were
weighed, overdosed with pentobarbital (200 mg/kg) and
perfused with 25 ml of 0.9% normal saline solution. Mice
were placed on an isothermal pad after anesthesia and
during perfusion to avoid artifactual tau phosphorylation
caused by reductions in body temperature [21]. Brains
were collected from the animals 1 hour after the last
tubastatin injection, following saline perfusion, and
were hemisected down the sagittal midline. One hemi-
sphere was dissected and frozen with dry ice for biochem-
ical studies. The second hemisphere was immersion fixed
in 4% paraformaldehyde for 24 hours, and cryoprotected
in successive incubations of 10%, 20% and 30% solutions
of sucrose for 24 hours in each solution. Subsequently,
the fixed hemispheres were frozen on a cold stage and
sectioned in the horizontal plane (25 μm thickness) on
a sliding microtome and stored in Dulbecco’s phosphate-
buffered saline with 10 mM sodium azide solution at 4°C.
Immunohistochemical/histological procedure and analysis
Eight sections, 200 μm apart, were chosen for analysis
using immunohistochemical procedural methods described
previously [22]. For each marker, floating sections from all
animals were placed in multi-sample staining trays, and
endogenous peroxidase was blocked (10% methanol, 10%
H2O2 in phosphate-buffered saline; 30 minutes). Tissue
samples were permeabilized (with 0.2% lysine, 1% Triton
X-100 in phosphate-buffered saline solution), and incubated
overnight in appropriate primary antibody (clonal names
in parentheses). Anti-N-terminus of human tau antibodies
(H150; Santa Cruz Biotechnology, Dallas, Texas, USA),
anti-phospho-tau at serine 396 antibodies (pSer396; Ana-
spec, Fremont, CA, USA), anti-phospho-tau at serine
199/202 antibodies (pSer199/202; Anaspec, Fremont,
CA, US), and anti-phospho-tau at serine 202 and threo-
nine 205 antibodies (biotinylated AT8; ThermoScienti-
fic, Waltham, MA, USA) were used in this study.
Sections were washed in phosphate-buffered saline and
then incubated in corresponding biotinylated secondary
antibody, except for AT8 (pSer199/Thr205; Vector La-
boratories, Burlingame, CA, USA). The tissue was again
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Elite® ABC kit (Vector Laboratories, Burlingame, CA, USA)
for enzyme conjugation. Finally, sections were developed
using 0.05% diaminobenzidine, 0.5% Ni2+ and 0.03% H2O2.
Tissue sections were then mounted onto slides, dehydrated,
and cover slipped. Each immunochemical assay omitted
some sections from primary antibody incubation to
evaluate nonspecific reaction of the secondary antibody.
Prior work with nontransgenic mice confirmed the speci-
ficity of the anti-tau antibodies for tau in rTg4510 mice.
Gallyas histology was performed as described previously
[23], using sections that were premounted on slides and then
air-dried for a minimum of 24 hours. The sections were rehy-
drated for 30 seconds prior to proceeding with the Gallyas
protocol. Slides were treated with 5% periodic acid for 5 mi-
nutes, washed with water, and incubated sequentially in silver
iodide (1 minute) and 0.5% acetic acid (10 minutes) solutions
prior to being placed in developer solution (2.5% sodium car-
bonate, 0.1% ammonium nitrate, 0.1% silver nitrate, 1% tung-
stosilicic acid, 0.7% formaldehyde). Slides were treated with
0.5% acetic acid to stop the reaction, incubated with 0.1% gold
chloride, placed in 1% sodium thiosulfate, and counterstained
with 0.1% nuclear fast red in 2.5% aqueous aluminum sulfate,
with each step separated by washes in water. Following a final
wash, slides were dehydrated and cover slipped.
Stained sections were imaged using a Zeiss Mirax150
digital scanning microscope (Carl Zeiss MicroImaging
GmbH Clinical 07740 Jena, Germany). The area of positive
stain in each hippocampal section was analyzed. The soft-
ware used hue, saturation and intensity to segment the image
fields. Thresholds for object segmentation were established
with images of high and low levels of staining to identify
positive staining over all intensity levels within the study.
These limits were held constant for the analysis of every sec-
tion in each study according to Gordon and colleagues [24].
Western blot analysis
Tissues for western analysis were prepared as described by
Carroll and colleagues [25]. Briefly, the dissected anterior
cortex tissue was weighed and resuspended in RIPA buffer
(50 mM Tris, 140 mM NaCl, 10% NP40, 10% sodium deox-
ycholate, 10% SDS), with protease inhibitor cocktail (Sigma-
Aldrich, St. Louis, MO, USA) and phosphatase inhibitor
cocktails I and II (Sigma-Aldrich, St. Louis, MO, USA). Tis-
sue was homogenized with a motorized pestle followed by a
brief (10 seconds) sonication pulse. Aliquots were collected
at this point for biochemical analysis and were referred to
as brain homogenate. Pierce BCA protein assay (Thermo-
Scientific, Waltham, MA, USA) was used to determine pro-
tein concentrations. For western analysis, 1 μg protein was
loaded for each sample. Antibodies against tau epitopes
pS396 and pS199/202 (AT8) were obtained from Anaspec,
while H150 antibody was obtain from Santa Cruz Biotech-
nologies. PHF1 antibody was kindly provided by DrPeter Davies. A monoclonal antibody against acety-
lated α-tubulin at Lys40 was used to measure α-tubulin
acetylation following treatment (clone 6-11B-1; Sigma-
Aldrich, St. Louis, MO, USA). Total α-tubulin levels were
measured using monoclonal anti α-tubulin antibody (clone
TU-01; ThermoScientific, Waltham, MA, USA).
Stereology
Methods of design-based (unbiased) stereology were used
to quantify hippocampal volumes with assistance from
the Stereologer system (Stereologer, St Petersburg, FL,
USA). For this study a complete series of sections
through the hippocampus was cut at a thickness set-
ting of 50 μm and stained with cresyl violet. From this
sample of sections, a systematic random sample of every
seventh section was used to estimate the total hippocampal
volume using the Cavalieri-point counting method [26].
Statistical analysis
Statistical analysis and regression plots of studies including
both transgenic and nontransgenic mice (behavior) was
performed using two-way analysis of variance followed
by Fisher’s protected least significant difference (PLSD)
post hoc means comparison test using StatView version
5.0.1 (SAS Institute Inc, Cary, NC, USA). Measures ex-
cluding nontransgenic mice (tau levels) were analyzed
by Student’s t test.
Results
To determine the therapeutic effect of HDAC6 inhibition
on tau pathology we administered tubastatin, which shows
potency and selectivity towards HDAC6 inhibition in vitro
and in vivo (IC50 = 15 nM for HDAC6) [6]. An equal
number of 5-month-old rTg4510 mice and nontrans-
genic littermates were treated with tubastatin or the
saline vehicle by daily intraperitoneal injection for
2 months. At week 6 mice were started on a 2-week be-
havioral test battery, and tissues were collected at the be-
ginning of week 9 (Figure 1A). Measurements of α-
tubulin acetylation were used to determine the efficacy of
the treatment in modifying the acetylation state of α-
tubulin at the Lys40 residue. Western blot analyses re-
vealed a greater than twofold rise in acetylated α-tubulin
to total α-tubulin in tubastatin-treated rTg4510 mice,
while a 1.5-fold rise was observed in nontransgenic mice
as compared with saline-treated littermates (Figure 1B,C).
Interestingly, we observed a reduction in the levels of
α-tubulin following tubastatin treatment of rTg4510 but
not nontransgenic mice (Figure 1B). Data analysis (nor-
malized to glyceraldehyde 3-phosphate dehydrogenase)
demonstrated that tubastatin administration significantly
induced acetylated α-tubulin levels in both nontransgenic
and transgenic animals compared with saline-treated litter-
mates (Figure 1C). These findings are indirectly indicative
Figure 1 Schematic presentation of the experimental design of the current study. (A) Transgenic rTg4510 mice (n = 12) and their
nontransgenic (ntg) littermates received daily intraperitoneal (i.p.) injections of either 25 mg/kg tubastatin or 0.9% saline. Behavior testing of
all animals was performed 2 weeks prior to tissue collection. (B) Inhibition of histone deacetylase 6 increased acetylation levels of α-tubulin
in vivo. Western blot analysis of brain homogenate from saline and tubastatin-treated ntg and rTg4510 animals were probed for acetylation
of α-tubulin at the Lys40 residue and total α-tubulin levels. (C) Analysis of acetylated α-tubulin ratio to total α-tubulin and glyceraldehyde
3-phosphate dehydrogenase (GAPDH) by Student’s t test confirmed a significant treatment effect of tubastatin in ntg (P = 0.08 and P < 0.05,
respectively) and rTg4510 animals compared with saline-treated littermates (P < 0.001 and P < 0.05, respectively). All data are presented as
mean of ratio ± standard error of the mean (SEM).
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tubulin acetylation in the brain.
One phenotype we have observed in the rTg4510 line
is increased open field activity. This was observed again in
these mice by a variety of measures, with more than twice
the distance traveled by the saline injected transgenic mice
relative to either nontransgenic group. Tubastatin was
able to completely reverse this effect of the transgene, and
reduced activity to a level comparable with both vehicle
and tubastatin-treated nontransgenic mice (Figure 2).
We also observed an effect of the tubastatin on freezing
behavior of the rTg4510 mice in the training trial for fear
conditioning (Figure 3A). Here the tubastatin increased
freezing in the rTg4510 mice relative to the nontransgenic
mice. By the end of the training period, increased freezing
was also observed in the vehicle-treated rTg4510 mice.
During the contextual recall trial of fear conditioning, all
mice exhibited full retention of the context, with close to100% freezing (Figure 3B). Similar results were seen in the
cued retention trial (data not shown).
Mice were then tested for spatial navigation memory
using the radial arm water maze task. This task assesses
reference memory of hidden platform location within a
pool divided into swim alleys. Entries into incorrect arms
are scored as errors. Here the vehicle-treated rTg4510
mice failed to demonstrate learning, while both nontrans-
genic groups achieved the criterion performance of less
than one error by the end of the second day of training
(Figure 4A). The tubastatin-treated rTg4510 mice showed
learning and had significantly fewer errors than the
vehicle-treated rTg4510 mice by the end of the task.
Moreover, these mice were not significantly different from
the nontransgenic mice, although the final mean value did
not quite reach the less than one error criterion we have
associated with good learning in this task. On the next day
the mice were subjected to a reversal task in the radial
Figure 2 Rescue of rTg4510 hyperactivity by tubastatin treatment.
Treatment of rTg4510 animals with tubastatin significantly decreased the
open field test distance travelled compared with the saline-treated
littermates (distance ± standard error of the mean, n= 6). Two-way
analysis of variance revealed an overall effect of genotype (P= 0.03) and
of treatment in rTg4510 mice (P= 0.03). Ntg, nontransgenic *P< 0.05.
Figure 3 Increased freezing in tubastatin-treated rTg4510 mice during th
significantly increases the percent freezing ability of the rTg4510 mice compare
of the fear conditioning training paradigm. Two-way analysis of variance follow
transgenic (tg; P < 0.0001) and nontransgenic (ntg; P < 0.038) animal groups c
exhibited high levels of freezing during the retention phase of the test, indica
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cation. This requires unlearning the prior location and
relearning the new platform location. Here the vehicle-
treated rTg4510 mice failed to learn the platform location,
while both groups of nontransgenic mice rapidly acquired
the new platform location. The tubastatin-treated rTg4510
mice were intermediate and significantly better than the
vehicle-treated rTg4510 mice, yet statistically worse than
the nontransgenic mice (Figure 4B).
Tissue sections were stained for a variety of tau isoforms.
Stains for total human tau levels with antibody H150 re-
vealed significant reductions in tubastatin-treated rTg4510
mice (nontransgenic mice have no detectable staining in
either group). This antibody stains both neurons (darkly)
and neuropil (lightly; Figure 5A,B,C,D,E,F, arrowhead).
The neuropil staining appears to be specific, as it is not
observed in brain regions lacking darkly stained neurons
(thalamus, brain stem) or found in nontransgenic mice
(not shown). Using the digital scanning microscope, we
performed image analysis measures separately in thee acquisition phase of fear conditioning. (A) Treatment with tubastatin
d with the saline-treated littermates (n= 6/group) in the acquisition phase
ed by Fisher’s PLSD test revealed a significant treatment effect in both
ompared with saline-treated mice of the same genotype. (B) All mice
ting recall of the context. *P < 0.05, ***P < 0.001.
Figure 4 Rescue of rTg4510 memory impairment by tubastatin treatment. Number of errors made (average ± standard error of the mean
(SEM)) while seeking the hidden platform in the radial arm water maze (RAWM). (A) Tubastatin-treated rTg4510 mice performed better in the
initial training (5 blocks of three trials) than vehicle-treated littermates (P = 0.002) and were not significantly different from the tubastatin-treated
nontransgenic (ntg) mice. (B) Reversal testing on day 3 (blocks 1 to 5) showed rescue of the memory impairment of rTg4510 mice following
histone deacetylase 6 inhibition compared with vehicle-treated littermates (two-way ANOVA and Fisher’s PLSD, P < 0.03). No significant difference
in either test was detected between vehicle-treated and tubastatin-treated nontransgenic animals (P > 0.05). *P < 0.05, **P < 0.01, *** P < 0.001.
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There was a roughly 50% reduction in total tau staining
in the tubastatin-treated mice, which was statistically
significant in the hippocampus and whole section mea-
surements (Figure 5G,H,I). We also stained sections for
a variety of forms of phosphorylated tau, and per-
formed Gallyas silver staining for aggregated tau. None
of these markers were modified by the tubastatin treat-
ment (Table 1). Given the positive correlation of tau
pathology with cognitive impairment in AD patients [3],
we examined how HDAC6 inhibition in vivo correlates
with behavior and pathophysiological changes measured
in treated rTg4510 mice (Figure 5J and Additional file 1).
The average number of errors made in the radial arm
water maze was plotted against the percent tau load
(H150) measured in the tissue of treated rTg4510 animals
(Figure 5J). Mice treated with tubastatin significantlyreduced the total tau levels, which is positively corre-
lated with the number of errors made during the
memory performance test (linear regression, r = 0.690,
P = 0.0130).
In addition, tissue stained with cresyl violet was used
to estimate the total hippocampal volume as described
previously [26]. Stereological analysis showed no effect
of tubastatin on the hippocampal volume of treated trans-
genic mice (Figure 5K), although a clear reduction in the
hippocampal volume was observed between rTg4510 mice
and nontransgenic littermates. Further, human tau load
(percent area) and the number of errors measured in
radial arm water maze testing were compared with the
hippocampal volume in all subsets of mice (Additional
file 1A,B). These data demonstrate that total tau levels
and memory performance was negatively correlated with
hippocampal volume.




































































































































Figure 5 Tubastatin treatment decreases total human tau levels in the mouse brains with no changes in hippocampal atrophy.
Representative images of brain tissue from (A, B, C) saline-treated and (D, E, F) tubastatin-treated rTg4510 mice stained for total human tau levels
(H150): (A), (D) cortex, and (B), (C), (E), (F) hippocampus (HPC) at two different magnifications (original magnifications 5×, 10× and 65×). (B, E)
Arrowhead, neuropil staining. Scale bar: 200 μm, 50 μm and 20 μm. (G, H, I) Quantification of immunostaining confirmed reduction of tau levels
following treatment: (G) cortex (P = 0.055), (H) HPC (*P < 0.05), and (I) entire hemisphere (**P < 0.001); Student’s t test, n = 6. Nontransgenic (ntg)
mice showed no immunoreactivity against human tau and were thus excluded from the statistical analyses. (J) Average number of errors made
in the radial arm water maze was plotted against the tau load (H150) measured as the percent positive area in tissue, n = 5/6, P = 0.0130, r = 0.690.
(K) HPC volume was measured by stereology. The reduced hippocampal volume observed in rTg4510 mice was not affected by the tubastatin
treatment (two-way ANOVA, **P < 0.001). Data presented as average +/- SEM.
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prepared tissue from the anterior cortex for western blot
analysis. Once again we found a significant reduction in
the total human tau measurement in the rTg4510 mice
treated with tubastatin (Figure 6A, lanes 11 to 15) as
compared with the saline-treated littermates (Figure 6A,B,Table 1 Histone deacetylase 6 inhibition decreases total tau l
Phosphorylation site Saline Tubastatin
Ser202/Thr205 (AT8) 0.8 ± 0.1 0.7 ± 0.1
Ser396 0.5 ± 0.1 0. 6 ± 0.1
Ser199/202 0.4 ± 0.1 0.5 ± 0.1
Gallyas stain (NFTs) 1.3 ± 0.2 1.7 ± 0.4
Total tau (H150) 2.2 ± 0.4 1.0 ± 0.2
Mean ± SEM and P values are indicated for immunopositive p-tau stain in the rTg45
Student’s t test, n = 6. NFT, neurofibrillary tangle.lanes 6 to 10). However, the western blot signals for phos-
phorylated tau at various epitopes were unaffected by the
drug treatment, consistent with the histological results.
Since tau antibodies recognize anti-human tau, no signal
was detected in nontransgenic animals in either group
(Figure 6A, lanes 1 to 5).evels but not pathological tau
P value Source
0.46 Ana Spec, EGT group, Fremont, CA, USA
0.34 Ana Spec, EGT group, Fremont, CA, USA
0.25 Ana Spec, EGT group, Fremont, CA, USA
0.21 Fischer scientific, Waltham, MA, USA
0.03 Santa Cruz Biotechnology, Inc. Dallas, Texas, USA
10 saline-treated versus tubastatin-treated animals.
Figure 6 Tubastatin treatment promotes reduction of total tau levels but not phosphorylated tau. (A) Levels of total human tau were
examined by immunoblotting with H150 antibody (1:1,000 in 1 μg protein) in saline-treated (lanes 1 and 2) or tubastatin-treated (lanes 3 to 5)
nontransgenic (ntg) mice, and in saline-treated (lanes 6 to 10) or tubastatin-treated (lanes 11 to 15) rTg4510 mice littermates. Levels of phosphorylated
tau present in the brain homogenate were examined using Ser396, Ser199/202 and PHF1 antibodies (1:1,000 dilution). No positive immunoreaction
was measured in saline-treated or tubastatin-treated ntg mice. (B) Quantification of immunoreactivity normalized to glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) revealed a significant decrease in levels of total tau in rTg4510 mice treated with tubastatin compared with saline-treated
rTg4510 mice (*P < 0.05). All data are presented as average SEM.
Selenica et al. Alzheimer's Research & Therapy 2014, 6:12 Page 9 of 12
http://alzres.com/content/6/1/12Discussion
The primary result of this study is the rescue of the memory
impairment found in the rTg4510 mouse line by a 2-month
treatment with tubastatin. This reversed both the hyper-
activity in these mice and the impaired spatial navigation
performance in the initial learning of the radial arm water
maze. The nontransgenic mice treated with the drug were
no different from the vehicle-treated mice on any of the
behavioral tests administered. Rescue of hyperactivity by
loss of HDAC6 function has also been recently reported
in animal models of amyloid-beta deposition [27]. Inter-
estingly, APPPS1-21 mice crossed with HDAC6−/− mice
improved their cognitive deficits without changing the
amyloid-beta plaque load. This qualitatively resembles the
effects of breeding amyloid-beta depositing mice onto the
tau null background (behavioral rescue without impacting
amyloid pathology). In our study, the rescue of the spatialnavigation should be considered partial, as the mice were
deficient compared with nontransgenic mice on the rever-
sal task (albeit improved relative to untreated transgenic
mice). One should note that at the initiation of treatment
(5 months) rTg4510 mice are already deficient on spatial
navigation tasks [12,28]. Moreover, they have already de-
veloped considerable pathology, measured histologically
[29]. Hence the residual impairment may reflect the im-
pact of pathology that developed prior to the treatment.
Several studies have demonstrated that neurodegeneration
and associated memory impairments can be rescued by
treatment with various HDAC inhibitors treatment (for
review see [30]). For instance, treatment of CK-p25 mouse
with the nonselective HDAC inhibitor sodium butyrate
(class I inhibitor) promoted learning ability and the re-
covery of long-term memory even after massive neuronal
loss [31]. Using a series of elegant experiments, Guan and
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type mice with suberoylanilide hydroxamic acid, a clinically
approved inhibitor of class I and class II HDACs, enhanced
memory formation more potently than sodium butyrate in
contextual fear conditioning training and memory testing
paradigm. The authors also provide evidence that gain of
HDAC2 function, but not HDAC1, impaired hippocampus-
dependent memory formation as well as working memory,
implicating HDAC2 in negatively regulating memory
formation in mice [32]. Interestingly, levels of HDAC2
were found to be increased by neurotoxic insults in vitro
in two mouse models of neurodegeneration, and in patients
with Alzheimer’s disease [33]. Other studies also demon-
strated that treatment of APP/PS1 mice with valproic acid
(class I inhibitor [34]) or trichostatin A (class I and class II
inhibitor [35]) rescued memory deficits in this model.
These studies support our findings that inhibition of
HDAC6 rescued both the hyperactivity and the impaired
spatial navigation performance of rTg4510 mice. The litera-
ture is less clear as to whether rescue of the behavior is
due to reduction of pathology (amyloid-beta or tau). For
instance, Ricobaraza and colleagues demonstrated that
treatment with sodium 4-phenylbutyrate (class I inhibitor)
reversed spatial memory deficits independent of changes
in amyloid-beta levels and senile plaque deposits, but
did reduce levels of pS202/Thr205 tau in 16-month-old
Tg2576 mice [36]. However, chronic administration of
sodium 4-phenylbutyrate in 6-month-old Tg2576 mice
(prior the onset of disease) prevented memory deficits
in these mice and demonstrated decreased levels of
amyloid-beta pathology [37]. In our study, behavior im-
provements following tubastatin treatment were associ-
ated with changes in the levels of total tau, not the
phosphorylated tau isoforms or the aggregated tau form-
ing argyrophilic deposits detected by Gallyas (argued to be
neurofibrillary tangles). This roughly 50% reduction was
found throughout the brain both histologically and by
western analysis, and is positively correlated with the
number of errors made in the radial arm water maze
by the mice treated with tubastatin. Superficially, this
would imply that the memory impairments on spatial
navigation tasks are associated more with the high
levels of total tau, rather than with any specific isoform
or aggregated tau. This is consistent with the observation
of Santacruz and colleagues that inhibition of transgene
expression in this mouse led to rescue of the memory im-
pairment, but had no effect on the continued accumula-
tion of abnormally phosphorylated or aggregated tau [12].
This would be consistent with reports that tau aggregation
appears to be self-propagating once initiated, and can be
spread to adjacent neurons [38,39].
In addition to modification of histones, cytosolic proteins
are also substrates for HDACs. Post-translational protein
acetylation is important in regulation of several cellularevents including microtubule stabilization and intracellu-
lar transport [40,41]. In our study, we took advantage of
the fact that α-tubulin is one of the main cytosolic sub-
strates of HDAC6. Inhibition of HDAC6 is known to
increase acetylation of α-tubulin on Lys40 [40], which was
confirmed by our data demonstrating that intraperitoneal
administration of tubastatin, a selective inhibitor of HDAC6
(Change back to IC50=15nM) [6], resulted in hypera-
cetylation of α-tubulin in the brain of the treated mice.
Although the mechanism by which tubastatin affects
microtubule stability was not investigated here, several
studies support this notion [41]. For instance, in
Charcot-Marie-Tooth disease it is suggested that the
axonopathy is due to destabilization of microtubules and
impaired axonal transport [7]. The rescue of this pheno-
type by tubastatin is suspected to be caused by improved
microtubule function associated with increased acetylation.
Consistent with this argument, a recent report found that
tubastatin restored mitochondrial transport in a cell model
of amyloid toxicity [42], while another recent study sug-
gested that inhibition of HDAC6 enzymatic activity by
tubastatin increases its direct binding to microtubules and
possibly enhanced microtubule stability in human breast
cancer cells (MCF-7) [43]. Improved axonal transport may
thus be one mechanism by which tubastatin is achieving its
benefits in this model.
Another interaction of HDAC6 was reported with tau
itself in a cell-based overexpression system [44]. Here
aggregates of HDAC6 and tau could be detected with
association occurring at the microtubule binding domain
of tau (using immunoprecipitation studies). Moreover,
these aggregates formed perinuclear structures resembling
aggresomes. HDAC6 inhibitors also reduced phosphoryl-
ation of tau at position 202/205 (AT180), but not at pos-
ition 396/404 (PHF-1). Given that the HDAC6 inhibitors
used by Ding and colleagues reduced phosphorylated tau
but had no apparent effect on total tau, it is uncertain
what the relevance of this association might be to the
present study. One should also note that Ding and col-
leagues reported that HDAC6 inhibitors did not block
the association between HDAC6 and tau [44]. A similar
interaction between tau and HDAC6 was observed by
Perez and colleagues using immunoprecipitation [45].
These authors also found in neuronal cultures that tau
could inhibit the deacetylation activity of HDAC6 in a
dose-dependent manner. They also argued that HDAC6
inhibitors were less effective in increasing tubulin acetyl-
ation in the presence of tau. However, given the twofold
elevation of tubulin acetylation with tubastatin in the
rTg4510 mouse, which expresses many fold more tau than
wild-type mice, this action of tau seems to be less import-
ant in vivo than in cell systems. After we initiated these
studies, a second mechanism by which HDAC6 inhibition
might affect tauopathy was described. Cook and colleagues
Selenica et al. Alzheimer's Research & Therapy 2014, 6:12 Page 11 of 12
http://alzres.com/content/6/1/12showed that, through acetylation of HSP90, HDAC6
regulates the degradation of tau in cell models [8]. When
HDAC6 activity is decreased in vitro, there is an in-
creased clearance of tau. Elevation of HDAC6 in cells
promotes accumulation of tau. These actions appear me-
diated through inhibition of p23 binding to acetylated
HSP90, reducing its affinity for client proteins and enhan-
cing their clearance. HDAC6 inhibition will thus bias the
actions of HSP90 towards degradation of its client pro-
teins, reducing the levels of tau.
Our data presented here, with a lowering of total tau,
are consistent with this mechanism of action. Notably,
these data provide multiple, related mechanisms by which
HDAC6 inhibition might have benefits in tauopathies.
One interesting observation is the finding that HDAC6
expression is increased by 52% in the Alzheimer’s disease
cortex and by 91% in the Alzheimer’s disease hippocam-
pus, when compared with young normal brains [46], as
tau pathology progresses from entorhinal to hippocampal
to neocortical regions [47]. Although the mechanism of
action by which tubastatin reduces total tau and improves
the behavior deficits of rTg4510 mouse models was not
investigated in this study, our data are the first to dem-
onstrate rescue of behavior phenotype and reduction of
total tau levels in vivo. Future experiments will exploit
the mechanism behind such events.
Conclusions
Unanswered questions include whether initiating HDAC6
inhibition earlier would not only prevent the behavioral
changes, but could also reduce the pathological changes
found in the rTg4510 mouse. A second question is whether
the benefits would be present in the absence of elevated
tau expression, such as after treating rTg4510 mice with
doxycycline. Benefits found in the presence of doxycycline
would imply that effects in stabilizing microtubules would
be a major mechanism, while loss of additional benefit of
tubastatin would suggest that the major effect of tubasta-
tin is due to lowering levels of total tau. In any case, these
data strongly support development of HDAC6 inhibitors,
such as tubastatin, as possible treatments for Alzheimer’s
disease and other tauopathies.
Additional file
Additional file 1: Is a figure showing hippocampal volume is
negatively correlated with total tau levels and memory performance.
(A) Total tau load measured in tissue (H150, % area) was plotted against the
hippocampal volume of rTg4510 and nontransgenic (ntg) animals, following
treatment (n = 5/6, P = 0.0001, r = 0.714). (B) The average number of errors
made in the radial arm water maze was plotted against the hippocampal
volume of rTg4510 and ntg animals (n = 5/6, P = 0.001, r = 0.657).
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